Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is a lipoprotein disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and an increased risk of premature atherosclerotic cardiovascular disease. Recent evidences have shown that several glycerophospholipid species were mar...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2025-01-01
|
| Series: | Research |
| Online Access: | https://spj.science.org/doi/10.34133/research.0629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849718530182742016 |
|---|---|
| author | Zhiyong Du Yu Wang Fan Li Xuechun Sun Yunhui Du Linyi Li Huahui Yu Chaowei Hu Haili Sun Xiaoqian Gao Lijie Han Zihan Zhang Jingci Xing Luya Wang Jianping Li Yanwen Qin |
| author_facet | Zhiyong Du Yu Wang Fan Li Xuechun Sun Yunhui Du Linyi Li Huahui Yu Chaowei Hu Haili Sun Xiaoqian Gao Lijie Han Zihan Zhang Jingci Xing Luya Wang Jianping Li Yanwen Qin |
| author_sort | Zhiyong Du |
| collection | DOAJ |
| description | Familial hypercholesterolemia (FH) is a lipoprotein disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and an increased risk of premature atherosclerotic cardiovascular disease. Recent evidences have shown that several glycerophospholipid species were markedly altered in experimental FH animals and exhibited diverse bioactivities. Nevertheless, the glycerophospholipid profiles and their associated biological implications in human FH remain largely unknown. In this study, we sought to comprehensively delineate the glycerophospholipid phenotypes in human FH and to investigate the functional roles of key FH-altered glycerophospholipid molecules on cholesterol metabolism. Targeted analysis of 328 glycerophospholipid metabolites was used to profile the differentiated alterations in patients with homozygous FH (HoFH; n = 181), heterozygous FH (HeFH; n = 452), and non-FH hypercholesterolemia (n = 382). Our findings revealed that the glycerophospholipid phenotypes of FH and non-FH hypercholesterolemia were dominated by a spectrum of metabolites involved in the lysophosphatidic acid (LPA) metabolism. Among the LPA features, palmitoyl-LPA (16:0) showed significant association with the clinical levels of LDL-C and total cholesterol in HoFH and HeFH populations. Using functional metabolomic strategy and murine FH model, we demonstrated that supplementation with LPA 16:0 elevated the plasma levels of LDL and free/esterified cholesterol and exacerbated the atherosclerotic lesions. Conversely, inhibition of autotaxin-mediated LPA 16:0 production significantly ameliorated dyslipidemia. Mechanistically, we uncovered that LPA 16:0 could disrupt hepatic cholesterol homeostasis by impairing cholesterol excretion and inhibiting primary bile acid synthesis. In summary, our study offers novel insights into lipid metabolism in human FH and posits that targeting LPA metabolism may represent a promising therapeutic strategy for reducing cholesterol levels in the FH population. |
| format | Article |
| id | doaj-art-4399cbb7a346485d9e470210c32b367e |
| institution | DOAJ |
| issn | 2639-5274 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | American Association for the Advancement of Science (AAAS) |
| record_format | Article |
| series | Research |
| spelling | doaj-art-4399cbb7a346485d9e470210c32b367e2025-08-20T03:12:20ZengAmerican Association for the Advancement of Science (AAAS)Research2639-52742025-01-01810.34133/research.0629Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial HypercholesterolemiaZhiyong Du0Yu Wang1Fan Li2Xuechun Sun3Yunhui Du4Linyi Li5Huahui Yu6Chaowei Hu7Haili Sun8Xiaoqian Gao9Lijie Han10Zihan Zhang11Jingci Xing12Luya Wang13Jianping Li14Yanwen Qin15Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Department of Cardiology, Peking University First Hospital, Beijing 100034, China.Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.Familial hypercholesterolemia (FH) is a lipoprotein disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and an increased risk of premature atherosclerotic cardiovascular disease. Recent evidences have shown that several glycerophospholipid species were markedly altered in experimental FH animals and exhibited diverse bioactivities. Nevertheless, the glycerophospholipid profiles and their associated biological implications in human FH remain largely unknown. In this study, we sought to comprehensively delineate the glycerophospholipid phenotypes in human FH and to investigate the functional roles of key FH-altered glycerophospholipid molecules on cholesterol metabolism. Targeted analysis of 328 glycerophospholipid metabolites was used to profile the differentiated alterations in patients with homozygous FH (HoFH; n = 181), heterozygous FH (HeFH; n = 452), and non-FH hypercholesterolemia (n = 382). Our findings revealed that the glycerophospholipid phenotypes of FH and non-FH hypercholesterolemia were dominated by a spectrum of metabolites involved in the lysophosphatidic acid (LPA) metabolism. Among the LPA features, palmitoyl-LPA (16:0) showed significant association with the clinical levels of LDL-C and total cholesterol in HoFH and HeFH populations. Using functional metabolomic strategy and murine FH model, we demonstrated that supplementation with LPA 16:0 elevated the plasma levels of LDL and free/esterified cholesterol and exacerbated the atherosclerotic lesions. Conversely, inhibition of autotaxin-mediated LPA 16:0 production significantly ameliorated dyslipidemia. Mechanistically, we uncovered that LPA 16:0 could disrupt hepatic cholesterol homeostasis by impairing cholesterol excretion and inhibiting primary bile acid synthesis. In summary, our study offers novel insights into lipid metabolism in human FH and posits that targeting LPA metabolism may represent a promising therapeutic strategy for reducing cholesterol levels in the FH population.https://spj.science.org/doi/10.34133/research.0629 |
| spellingShingle | Zhiyong Du Yu Wang Fan Li Xuechun Sun Yunhui Du Linyi Li Huahui Yu Chaowei Hu Haili Sun Xiaoqian Gao Lijie Han Zihan Zhang Jingci Xing Luya Wang Jianping Li Yanwen Qin Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia Research |
| title | Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia |
| title_full | Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia |
| title_fullStr | Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia |
| title_full_unstemmed | Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia |
| title_short | Targeting Lysophosphatidic Acid Ameliorates Dyslipidemia in Familial Hypercholesterolemia |
| title_sort | targeting lysophosphatidic acid ameliorates dyslipidemia in familial hypercholesterolemia |
| url | https://spj.science.org/doi/10.34133/research.0629 |
| work_keys_str_mv | AT zhiyongdu targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT yuwang targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT fanli targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT xuechunsun targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT yunhuidu targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT linyili targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT huahuiyu targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT chaoweihu targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT hailisun targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT xiaoqiangao targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT lijiehan targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT zihanzhang targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT jingcixing targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT luyawang targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT jianpingli targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia AT yanwenqin targetinglysophosphatidicacidamelioratesdyslipidemiainfamilialhypercholesterolemia |